Journal
RHEUMATOLOGY
Volume 49, Issue 6, Pages 1184-1188Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keq062
Keywords
Infliximab; Eosinophilic fasciitis; Case report; Case series; Anti-tumour necrosis factor antagonists
Categories
Funding
- National Institutes of Health [NIAMS K23 AR053858-03]
- Scleroderma Foundation
Ask authors/readers for more resources
Objective. EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate-to high-dose glucocorticoids with or without use of immunosuppressives. Methods. We report three cases of steroid-resistant EF in clinical practice who were treated with 3 mg/kg every 8 weeks infliximab therapy. Results. All patients noticed an improvement in their symptoms, joint contractures and skin thickening within 8 weeks of starting infliximab therapy, ultimately leading to a drug-free remission (range 1-3 years). Conclusion. Based on this and other reported cases, infliximab may be beneficial in patients with steroid-resistant EF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available